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a  b  s  t  r  a  c  t
Greater  progress  has  been  made  in  the  clinical  application  of  cartilage  regenerative  medicine,  com-
pared  with  that  of  other  organs.  A typical  example  of cartilage  regenerative  medicine  is autologous
chondrocyte  implantation,  in which  chondrocytes  isolated  from  the  patient’s  cartilage  are  cultured  and
injected  into  the  cartilage  defects  in a liquid-  or gel-form.  However,  the  classic  autologous  chondrocyte
implantation  has  been  applicable  to  only  limited  diseases,  including  focal  cartilage  lesion.  Therefore,
we  developed  “implant-type”  tissue-engineered  cartilage  that  shows  mechanical  strength  and  three-
dimensional  shape.  This  type  of  tissue-engineered  cartilage  uses  scaffold  composed  of  atelocollagenhondrocyte
issue  engineering
caffold
hydrogel  and  poly-l-lactic  acid  porous  material,  which  is  administered  with  cultured  autologous  auricular
chondrocytes.  Its  clinical  application  to nasal  deformity  of  cleft  lip  and  palate  patients  has  been  ongoing
at  present.  This  review  presents  an  overview  of  the  current  situation  regarding  cartilage  regenerative
medicine,  as  well  as  introducing  our  research  and  the  development  of  implant-type  tissue-engineered
cartilage  for  the  cleft-lip  nose.  The  discussion  of  the  future  development  of  regenerative  medicine  is  also
mentioned.© 2012 Japanese Stomatological Society. Published by Elsevier Ltd. All rights reserved.
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In regenerative medicine, a small volume of tissue is biopsied
from a patient or a donor, and the cells isolated from the tis-
sue are cultured in vitro for proliferation or differentiation. The
cultured cells or the constructs consisting of those cells are then
implanted into the patient. Such methods that are used in regen-
erative medicine reconstruct a body part to compensate for organs
evier Ltd. All rights reserved.
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hat are damaged or have reduced function. Proof of concept of
egenerative medicine was provided a surprisingly long time ago.
reen and Rheinwald from Massachusetts Institute of Technology
eeded epidermal cells on top of 3T3 cells from Swiss mouse and
uccessfully cultivated epidermal cells in multi-layer in 1975 [1],
ndicating the feasibility of skin regenerative medicine. Later, this
ultured epidermal cell sheet was used to treat burn patients and
as developed as commercial products in the 1980s.
Regenerative medicine attracted further global attention, once
he possibility of tissue engineering-type regenerative medicine
ncorporating elements of materials science was reported in the
ournal Science by Langer and Vacanti [2] from Harvard University.
hey deﬁned cells, stimulating factors (growth factors), and scaf-
old materials as the three major factors in tissue engineering, and
roposed the possibility of creating various tissues and organs with
heir shapes and functions by changing the combinations of those
hree factors.
The  reports on the production of a cloned animal [3] and the
stablishment of human embryonic stem cells (ES cells) [4] or
nduced pluripotent stem cells (iPS cells) [5] further suggested the
otential for regenerative medicine to become a versatile medi-
al tool. Further, in the 2000s, Okano and co-workers from Tokyo
omen’s Medical University-Waseda University Joint Institution
or Advanced Biomedical Sciences used temperature-responsive
ulture  dishes to develop cell sheet technology, which can be used
o produce cultured cells in a sheet form with preservation of inter-
ellular junctions and surrounding extracellular matrix [6]. The
echnology has been applied to various tissues, such as cornea, car-
iac muscle, digestive tract, liver, and periodontal membrane, while
ood clinical results have been reported for some tissues, including
he cornea and cardiac muscle [7].
. Cartilage as the target of regenerative medicine
Various tissues and organs have become the targets for
ctive research in regenerative medicine. In addition to skin and
ornea, clinical application has progressed in cartilage regenera-
ive medicine. Cartilage is widely present throughout the body,
ncluding nose, ear, trachea, joint, and intervertebral disc. This tis-
ue plays an important role in maintaining the body shape, daily
ovement, and exercise. The cartilage is composed of circular or
val-shaped chondrocytes, surrounded by large amounts of extra-
ellular matrices. The extracellular matrices in cartilage are termed
s cartilaginous matrices, which are rich in type II collagen and pro-
eoglycans. These organic materials form a dense meshwork in the
hysiological cartilage, containing a large volume of water, yield-
ng a rupture strength of approximately 35 MPa, Young’s modulus
f approximately 20 MPa, and equilibrium compression modulus of
pproximately 330 kPa, which are higher than those of other tissues
8,9].
However, cartilage is affected by various diseases including con-
enital morphological anomalies such as cleft lip and palate, trauma
o joint, large deﬁcits after surgery for tumors or cancers, ageing-
elated diseases such as osteoarthritis, and inﬂammatory diseases
uch as rheumatoid arthritis. Once the cartilage tissues are dam-
ged due to those disorders, it becomes difﬁcult to maintain the
orphology of face or body, as well as resulting in deterioration
f daily activities, such as mastication and walking, which signiﬁ-
antly interferes with the patient’s quality of life. As the cartilage
issues have limited capacity for self-repair, those that are once
amaged are not likely to be repaired from natural healing or by
se of medication. Thus, cartilage diseases have traditionally been
reated with transplantation of the autologous cartilage, or replace-
ent with artiﬁcial joints. However, there are issues with those
ypes of treatment, such as durability, infection, and invasivenessnational 10 (2013) 15– 19
of  donor sites. Therefore, novel treatments involving regenerative
medicine are anticipated.
3.  Current conditions of cartilage regenerative medicine
As  a typical example of cartilage regenerative medicine, autol-
ogous chondrocyte implantation (ACI) has been implemented
worldwide as the practical method of cartilage regenerative
medicine. The original ACI method was designed to treat focal
defects of articular cartilage caused by athletic trauma or osteo-
chondritis disecans. A small volume of articular cartilage was
collected from edge of joint, and was digested by enzyme to iso-
late chondrocytes. After the cells were multiplied in culture, those
cells in suspension were placed into the deﬁcit site, which was
then covered by a periosteal patch to prevent leakage (Fig. 1A) [10].
The original ACI method was  developed commercially by Genzyme
in the USA, and the products sold as CarticelTM have been used
in over 20,000 cases of athletic injuries and osteochondritis dis-
ecans over the past 10–15 years. However, the number of cases
using Carticel represents less than 1% of the number of artiﬁcial
joint surgeries performed for osteoarthritis during the same period
(approximately 6 million cases), suggesting that applicability of the
current cartilage regenerative medicine, ACI remains limited. One
report also highlighted adverse events in the original ACI method,
such as graft dislocation, delamination, and thickening of periosteal
patches [11]. A systematic review of the original ACI method also
indicated that there was  no signiﬁcant clinical advantage compared
to drilling (microfracture method) and cylinder or mosaic plasty
by autologous cartilage and bone [12]; therefore, this method has
much room for improvement.
Also  in the oral and maxillofacial region, ACI has been clinically
applied to the patients whose silicone implants used for cosmetic
rhinoplasty had been removed due to infection or their exposure to
the skin [13]. Auricular cartilage was sampled from those patients
under local anesthesia, and the chondrocytes were isolated and
cultured using autologous serum to prepare the cells for injection.
Cultured autologous auricular chondrocytes were injected on top
of the nasal bones or into a subcutaneous pocket, where the sili-
cone implants had been inserted. The saddleback of the nose was
externally ﬁxed for 7 days. After the ﬁrst 7 days, the patients ﬁxed
the saddleback of the nose only at night using tapes for 3 weeks to
obtain subcutaneous regenerative cartilage. The same group also
performed treatment, in which this type of subcutaneous regenera-
tive cartilage was  created in the subcutaneous tissue of the patient’s
abdomen, was extracted, and then fabricated to the desired shape
ex vivo, following the re-implantation of the fabricated regener-
ative tissue [14]. Although this method allowed implantation of
shaped regenerative tissues to the treatment site, three sessions
of surgery were required, i.e. biopsy of donor cartilage, implanta-
tion of chondrocytes into the abdominal skin, and reimplantation of
regenerative cartilage. Other than the donor site and the treatment
site, a surgical wound was created on a third site, the abdomen.
Furthermore, the amount and shape of regenerative cartilage har-
vested from the abdomen by implanting chondrocytes could not be
strictly managed, and it was, therefore, difﬁcult to predetermine the
ﬁnal shape of the regenerative cartilage before surgery. In addition,
from the time when cartilage was biopsied, it took over 7 months
before the shaped regenerative cartilage was ﬁnally implanted into
the treatment site.
4.  Modiﬁcation of autologous chondrocyte implantation by
introducing scaffold biomaterials
As mentioned above, the classical ACI involved injecting a cell
suspension into the area of focal cartilage defects. However, to
K. Hoshi et al. / Oral Science International 10 (2013) 15– 19 17
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iig. 1. Various methods of autologous chondrocyte implantation (ACI). Various typ
ith  collagen membrane (B), or all-in-one type using animal-derived biomaterials 
epair nasal deformity in cases of cleft lip and palate, which is
he major target of oral and maxillofacial surgery, the regenerative
issues that are implanted into the patient’s body must have the
echanical strength and three-dimensional conﬁguration corre-
ponding to the nose. To expand the areas of applicability, including
asal deformity in cleft lip and palate, microtia, or end stage of
steoarthritis, all of which damage the cartilage over large areas,
t is necessary to create a regenerative cartilage with appropriate
trength and three-dimensional shape. To do so, the introduction
f scaffold materials to reinforce the mechanical strength of regen-
rative cartilage is regarded essential.
On the other hand, some biomaterials have recently been
ntroduced to overcome other weak points of the classical ACI.
n order to decrease the invasion during harvesting of periosteum
hat was used as the patch in the original ACI method, or to pre-
ent the periosteal thickening as an adverse event, collagen ﬁlm
Chondro-GideTM, Geistlich Biomaterials, Wolhusen, Switzerland)
as used instead of periosteal patches (Fig. 1B) [15,16]. In addition,
ll-in-one style of regenerative cartilage has been developed, which
oes not use periosteal patches, but instead makes use of a porous
aterial composed of collagen (MaixTM, Matricel, Herzogenrath,
ermany) or hyaluronic acid (Hyaff-11TM, Fidia Advanced Biopoly-
ers, Padua, Italy or Hyalograft CTM, Anika Therapeutics, Bedford,
A, USA), both of which are derived from animals and have high cell
etention capability [15,17–19]. The cultured chondrocytes were
nﬁltrated into those biomaterials, and were subsequently admin-
stered into the defective part of the joint, without using periosteal
atches (Fig. 1C) [15]. The all-in-one style of the regenerative car-
ilage allowed use of arthroscopic approaches, and thus reduced
perative invasion, compared with the original ACI method that
equired the harvesting of periosteum and open surgery. This has
lready been clinically applied in some countries [20], and the
eports of clinical outcomes are waited.
In Japan, a group led by Professor Ochi from the Department of
rthopedic Surgery, Hiroshima University, has developed a method
n which the chondrocytes were embedded into atelocollagenCI have been developed, including original one (A), substitution of periosteal patch
gel  and were three-dimensionally cultured [21]. The atelocolla-
gen is a collagen with telopeptide located at both ends of the
collagen molecule removed by enzyme treatment, thus reduc-
ing the immune activity and antigenicity of the collagen. This
group embedded cultured chondrocytes in the atelocollagen gel
for approximately 1 month, then administered it as a single mass
to the defects of articular cartilage in the patients. This method
of treatment could improve implant operability by embedding the
cells in gel. Further, chondrocytes that are cultured onto conven-
tional culture dishes have reduced cartilaginous matrix-producing
capacity, i.e. they undergo dedifferentiation. Thus, atelocollagen
three-dimensional embedded culture may  replicate the physiolog-
ical three-dimensional environment of chondrocytes, and suppress
the progress of dedifferentiation caused by conventional cell cul-
ture [21,22]. This technology was  transferred to Japan Tissue
Engineering Co., Ltd. Aichi, Japan, and has been undergoing clinical
studies and commercial development.
However, the biomaterials used in currently modiﬁed ACI, such
as collagen and hyaluronic acid, were mainly materials derived
from animal tissues. Although those materials have great cell afﬁn-
ity and biodegradability, they become soft when they absorb water,
and do not have sufﬁcient mechanical strength to support a load.
To create the regenerative cartilage that satisﬁes the need for its
clinical application and to expand the application of cartilage regen-
erative medicine, the technology for tissue-engineered cartilage
constructs that possess a sufﬁcient mechanical strength and can
be implanted not only into focal cartilage defects but also for larger
cartilage damage must be established.
5. Challenges to create an implant-type tissue-engineered
cartilage that has both mechanical strength and
three-dimensional shapeIn  order to provide the regenerative tissue with mechanical
strength, we examined the use of biodegradable polymers instead
of animal-derived materials. Biodegradable polymers are termed
18 K. Hoshi et al. / Oral Science Inter
Fig. 2. Implant-type tissue-engineered cartilage. We  administered the cultured
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[utologous  auricular chondrocytes into the scaffold composed of atelocollagen
ydrogel  and the poly-L-lactic acid (PLLA) porous material, to create the implant-
ype  tissue-engineered cartilage.
or organic compounds that slowly undergo hydrolysis in vivo,
nd that are ultimately broken down into water and carbon diox-
de. Well-known biodegradable polymers include poly-l-lactic acid
PLLA), which has shown good clinical results as a material of plates
nd screws to ﬁx bones, polyglycolic acid (PGA), and poly-lactic
cid-co-glycolic acid (PLGA), which are materials used to make
bsorbable surgical sutures. We  attempted to use such polymers
o create porous material, and examined their use as scaffold for
issue-engineered cartilage [23]. Those scaffolds retained mechan-
cal strength even after implantation because they maintained
igidity even after hydration, and we were able to add a three-
imensional shape corresponding to the area with cartilage defect.
he pore size of the porous material cannot be too large, which
akes it difﬁcult to seed the cells uniformly within the porous
aterial, nor can it be too small, because it is difﬁcult to achieve
ufﬁcient inﬁltration of cells into the inner part of the porous mate-
ial. During the development of tissue-engineered cartilage, we
elected the scaffold with relatively large pore size (pore diame-
er of 0.3 mm),  and administered cells mixed with atelocollagen gel
hat prevents them from easily ﬂowing out from the porous mate-
ial [24,25]. The use of PLGA, which undergoes rapid breakdown
fter implantation, interfered with the maturation of regenerative
artilage, because it caused severe foreign body reaction during
he ﬁrst month after implantation, which period is important for
he establishment of cartilage regeneration [26,27]. Therefore, we
hose PLLA, which undergoes relatively slow biodegradation, to
educe foreign body reaction in the early stage after implanta-
ion [28]. As a result, we have established the tissue-engineered
artilage with mechanical strength equivalent to that of physiolog-
cal cartilage tissue, using a scaffold system with porous material
omposed of PLLA and atelocollagen (Fig. 2). We  term such a regen-
rative cartilage as “implant type”, because it is not injected, but can
e surgically implanted into the body.
At present, we have worked on clinical applications of the
mplant-type tissue-engineered cartilage for nasal deformity in
left lip and palate. Traditionally, because we could not obtain a
uitable rod-shaped autologous cartilage from the patients, iliac
one was used instead of the autologous cartilage. However, the
liac bones resulted in issues such as hard nose or fracture of
ransplants [29]. Thus, the clinical use of the implant-type tissue-
ngineered cartilage, which allows reconstruction of the cleft-lip
oses with physical properties close to physiological cartilage, has
een highly anticipated. A clinical study to use scaffold composed
f atelocollagen hydrogel and the PLLA porous material, which is
dministered with cultured autologous auricular chondrocytes, to
reate the implant-type tissue-engineered cartilage for treatment
f nasal deformity in cleft lip and palate, was under review based
n The Ethics Guidelines for Clinical Research with Human Stem Cells
[national 10 (2013) 15– 19
by  the Ministry of Health, Labor, and Welfare of Japan, and has
been conducted after approval by the Ministry of Health, Labor, and
Welfare of Japan on 15 March, 2011 (UMIN Clinical Trials Registry
ID5472, http://www.umin.ac.jp/ctr/index-j.htm).
6.  Future prospects
The  classic ACI by the injection of cultured chondrocytes
has shown good results as a ﬁrst-generation cartilage regener-
ative medicine in repairing focal cartilage defects. In order to
expand the application of cartilage regenerative medicine, we
should actively introduce scaffold materials and improve function-
ality and operability of tissue-engineered constructs. In addition,
studies on the development of serum-free culture medium and
suppression of cell differentiation during proliferation should be
addressed. Furthermore, support technologies including cell iso-
lation methods, three-dimensional culture devices, automated
systems for mass cultivation, and the evaluation technology of
tissue-engineered cartilage, should also be enhanced. Using those
approaches to establish treatment systems based on cartilage
regenerative medicine, we would further expand the indication of
regenerative medicine.
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